Pro Share Advisors LLC Intra Cellular Therapies, Inc. Transaction History

Pro Share Advisors LLC

  • $42.5 Billion
  • Q4 2024

A detailed history of Pro Share Advisors LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 5,020 shares of ITCI stock, worth $643,815. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,020
Previous 6,244 19.6%
Holding current value
$643,815
Previous $456,000 8.11%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$71.19 - $91.57 $87,136 - $112,081
-1,224 Reduced 19.6%
5,020 $419,000
Q3 2024

Nov 13, 2024
SELL
$67.99 - $80.84 $932,890 - $1.11 Million
-13,721 Reduced 68.73%
6,244 $456,000
Q2 2024

Aug 13, 2024
SELL
$64.76 - $79.84 $236,762 - $291,895
-3,656 Reduced 15.48%
19,965 $1.37 Million
Q1 2024

May 08, 2024
BUY
$64.37 - $75.65 $126,293 - $148,425
1,962 Added 9.06%
23,621 $1.63 Million
Q4 2023

Feb 14, 2024
BUY
$46.37 - $73.65 $148,801 - $236,342
3,209 Added 17.39%
21,659 $1.55 Million
Q3 2023

Nov 13, 2023
BUY
$52.09 - $64.1 $2,969 - $3,653
57 Added 0.31%
18,450 $961,000
Q2 2023

Aug 10, 2023
BUY
$54.67 - $66.44 $57,075 - $69,363
1,044 Added 6.02%
18,393 $1.16 Million
Q1 2023

May 11, 2023
SELL
$43.8 - $56.99 $99,557 - $129,538
-2,273 Reduced 11.58%
17,349 $939,000
Q4 2022

Feb 02, 2023
BUY
$44.07 - $54.45 $70,379 - $86,956
1,597 Added 8.86%
19,622 $1.04 Million
Q3 2022

Nov 04, 2022
BUY
$42.7 - $59.99 $16,524 - $23,216
387 Added 2.19%
18,025 $840,000
Q2 2022

Aug 01, 2022
SELL
$43.0 - $65.64 $300,785 - $459,151
-6,995 Reduced 28.4%
17,638 $1.01 Million
Q1 2022

May 10, 2022
SELL
$38.74 - $62.09 $88,327 - $141,565
-2,280 Reduced 8.47%
24,633 $1.51 Million
Q4 2021

Feb 08, 2022
BUY
$35.2 - $53.42 $16,755 - $25,427
476 Added 1.8%
26,913 $1.41 Million
Q3 2021

Nov 12, 2021
SELL
$28.72 - $42.49 $186,306 - $275,632
-6,487 Reduced 19.7%
26,437 $986,000
Q2 2021

Aug 13, 2021
BUY
$29.3 - $44.5 $117,200 - $178,000
4,000 Added 13.83%
32,924 $1.34 Million
Q1 2021

May 14, 2021
BUY
$30.8 - $39.51 $57,380 - $73,607
1,863 Added 6.88%
28,924 $981,000
Q4 2020

Feb 09, 2021
BUY
$23.34 - $32.22 $191,458 - $264,300
8,203 Added 43.5%
27,061 $861,000
Q3 2020

Nov 13, 2020
BUY
$17.61 - $31.86 $13,454 - $24,341
764 Added 4.22%
18,858 $484,000
Q2 2020

Aug 03, 2020
BUY
$14.35 - $26.64 $86,186 - $159,999
6,006 Added 49.69%
18,094 $464,000
Q1 2020

May 15, 2020
SELL
$12.31 - $33.12 $72,629 - $195,407
-5,900 Reduced 32.8%
12,088 $186,000
Q4 2019

Feb 12, 2020
SELL
$7.26 - $38.49 $14,679 - $77,826
-2,022 Reduced 10.1%
17,988 $617,000
Q3 2019

Nov 12, 2019
SELL
$7.47 - $14.03 $6,162 - $11,574
-825 Reduced 3.96%
20,010 $149,000
Q2 2019

Aug 13, 2019
SELL
$10.65 - $14.29 $29,383 - $39,426
-2,759 Reduced 11.69%
20,835 $270,000
Q1 2019

May 15, 2019
BUY
$10.9 - $14.09 $3,466 - $4,480
318 Added 1.37%
23,594 $287,000
Q4 2018

Feb 14, 2019
SELL
$10.36 - $20.96 $46,775 - $94,634
-4,515 Reduced 16.25%
23,276 $265,000
Q3 2018

Nov 14, 2018
SELL
$17.77 - $22.9 $19,422 - $25,029
-1,093 Reduced 3.78%
27,791 $603,000
Q2 2018

Aug 13, 2018
SELL
$17.33 - $23.4 $30,795 - $41,581
-1,777 Reduced 5.8%
28,884 $510,000
Q1 2018

May 14, 2018
SELL
$15.16 - $25.49 $76,467 - $128,571
-5,044 Reduced 14.13%
30,661 $645,000
Q4 2017

Feb 14, 2018
BUY
$14.27 - $16.79 $127,416 - $149,917
8,929 Added 33.35%
35,705 $517,000
Q3 2017

Nov 13, 2017
BUY
$10.77 - $22.1 $16,230 - $33,304
1,507 Added 5.96%
26,776 $423,000
Q2 2017

Aug 11, 2017
BUY
N/A
25,269
25,269 $314,000

Others Institutions Holding ITCI

# of Institutions
417
Shares Held
88.5M
Call Options Held
284K
Put Options Held
105K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $12.1B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email